BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Argus Health
QuintilesIMS
Julphar
Express Scripts
Harvard Business School
Covington
Citi
McKinsey
Healthtrust

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 018440

« Back to Dashboard

NDA 018440 describes M.V.C. 9+3, which is a drug marketed by Abraxis Pharm and is included in one NDA. Additional details are available on the M.V.C. 9+3 profile page.

The generic ingredient in M.V.C. 9+3 is ascorbic acid; biotin; cyanocobalamin; dexpanthenol; ergocalciferol; folic acid; niacinamide; pyridoxine hydrochloride; riboflavin 5'-phosphate sodium; thiamine hydrochloride; vitamin a; vitamin e. There are six drug master file entries for this compound. Additional details are available on the ascorbic acid; biotin; cyanocobalamin; dexpanthenol; ergocalciferol; folic acid; niacinamide; pyridoxine hydrochloride; riboflavin 5'-phosphate sodium; thiamine hydrochloride; vitamin a; vitamin e profile page.
Summary for 018440
You have an error in your SQL syntax; check the manual that corresponds to your MariaDB server version for the right syntax to use near 'SODIUM','THIAMINE HYDROCHLORIDE','VITAMIN A','VITAMIN E') AND hsdb_drugname IS N' at line 1
Tradename:M.V.C. 9+3
Applicant:Abraxis Pharm
Ingredient:ascorbic acid; biotin; cyanocobalamin; dexpanthenol; ergocalciferol; folic acid; niacinamide; pyridoxine hydrochloride; riboflavin 5'-phosphate sodium; thiamine hydrochloride; vitamin a; vitamin e
Patents:0